COMPASS Pathways plc (FRA:5Y6)

Germany flag Germany · Delayed Price · Currency is EUR
4.600
+0.120 (2.68%)
At close: Dec 1, 2025
9.52%
Market Cap432.79M
Revenue (ttm)n/a
Net Income (ttm)-202.26M
Shares Outn/a
EPS (ttm)-2.33
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volume98
Open4.620
Previous Close4.480
Day's Range4.600 - 4.620
52-Week Range2.100 - 6.850
Betan/a
RSI42.98
Earnings DateFeb 26, 2026

About COMPASS Pathways

COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. The company was incorporated in 2020 and is headquartered in London, th... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2020
Employees 166
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 5Y6
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

There is no news available yet.